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Original article
Baseline metabolic tumor volume calculation using different 
SUV thresholding methods in Hodgkin lymphoma patients: 
interobserver agreement and reproducibility across software 
platforms
Francesca Tutinoa, Giulia Puccinia, Flavia Linguantia, Benedetta Puccinib,  
Luigi Rigaccic, Sofya Kovalchukb, Roberto Sciagràa and Valentina Bertia  
Aim: Although it is not yet used in clinical practice, 
metabolic tumor volume (MTV) assessed on the baseline 
FDG-PET has shown consistent prognostic value in 
various lymphoma types. The aim of our study was to 
compare interobserver agreement and reproducibility 
across platforms of MTV calculation using different SUV 
thresholding methods in a large series of patients with 
newly diagnosed Hodgkin lymphoma.
Materials and methods: We retrospectively studied 
121 patients. MTV at baseline FDG-PET was independently 
computed by three readers with three programs of semi-
automatic segmentation, Fiji, LifeX, and Accurate. MTV 
measurement was performed with different thresholds: 
SUV >2.5, SUV >4, and SUV >41% of SUV max.
Results: At inter-observer agreement analysis all 
Intraclass Correlation Coefficients (ICCs) were excellent 
(ICC >0.9), except for Accurate SUV >41% of SUV max 
(ICC = 0.8). The highest correlations were obtained at 
the SUV >4 threshold. The second best was SUV >2.5 
threshold. Regarding reproducibility across software, 
we found statistically significant differences between 
Fiji versus LifeX and Accurate at fixed thresholds and 
between LifeX and Accurate at SUV >41% of SUV max, 
while no significant differences emerged between LifeX 
and Accurate using fixed thresholds.
Conclusion: The three SUV thresholds studied are all 
suitable for MTV calculation in terms of reproducibility. 
The best reproducibility is achieved using fixed thresholds, 
both SUV >4 and SUV >2.5. If more than one software 
has to be used in a study, we suggest the use of fixed 
thresholds and the platforms LifeX and Accurate. Nucl 
Med Commun 42: 284–291 Copyright © 2020 Wolters 
Kluwer Health, Inc. All rights reserved.
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Introduction
In recent years, the use of metabolic tumor volume 
(MTV) at baseline PET evaluation has been promoted to 
complement the currently used clinical prognostic scores, 
to better stratify patients based on the risk of recurrence 
and to tailor treatment. MTV has shown to be consistently 
prognostic across many lymphoma types: diffuse large B 
cell lymphoma [1,2], Hodgkin lymphoma [3–6], follicular 
lymphoma [7], and peripheral T cell lymphoma [8].
A number of methods and software platforms was used 
to calculate MTV: algorithms with fixed SUV thresh-
olds, adaptive thresholds, and more advanced algorithms 
with ‘perimeter of interest’ [9]. The most used thresh-
olding methods were the fixed threshold SUV >2.5 and 
the per-lesion threshold SUV >41% of SUV max, recom-
mended by EAMN [10]. The heterogeneity of the meth-
ods led to different cut-offs for prognostic stratification 
and there is need to standardize MTV measurement 
before it can be implemented in clinical protocols for the 
patient benefit [11].
An ideal method for MTV measurement must be highly 
reproducible, not only inter-observer but also across soft-
ware, accurate and precise, without forgetting user-friend-
liness, necessary for application in a busy clinical setting 
(Boellaard R, Buvat I. Challenges of (total) metabolic active 
tumour volume measurements in lymphoma FDG PET/CT 
studies; Mikhaeel G. Can we use MTV in Clinical Practice? 
What should we expect? PILM 2018 powerpoint presenta-
tions). Reproducibility is of primary interest and appears 
to be more important than accuracy, since a gold standard 
for the ‘true’ volume of disease is lacking in lymphomas 
(Buvat I. How to choose a method for MTV measurement in 
lymphoma? PILM2018 powerpoint presentation).
Several studies have investigated methodological aspects 
of MTV measurement. These studies focused mainly on LWW
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method comparison, proving that MTV value strongly 
depends on the threshold used to outline it, and paid atten-
tion to inter-observer agreement and software reproduc-
ibility. Barrington et al. in 147 patients with diffuse large 
B cell lymphoma measuring MTV with the thresholds 
SUV >2.5, SUV >41% of SUV max and SUV > mean liver 
uptake (PERCIST), found excellent correlations between 
two readers using each method. The same group, with 
the threshold SUV >2.5 only, studied the reproducibility 
between commercial software and its in-house made soft-
ware, which resulted excellent [1]. Cottereu et al. in a large 
series of 106 patients with peripheral T cell lymphoma 
demonstrated the non-inferiority of fixed SUV thresholds 
compared to adaptive methods on prediction of prognosis 
[8]. The group of Kanoun et al. studied 59 patients with 
Hodgkin lymphoma with fixed SUV thresholds (SUV 
>2.5 and SUV >41% of SUVmax) and thresholds based on 
SUV max of the liver, finding cutoffs significantly differ-
ent across the methods but all well related to prognosis. 
Also in this study, the inter-observer agreement between 
two readers was excellent, while significant differences in 
MTV values emerged in software comparison [12].
In the present study, on a large series of patients with 
newly diagnosed Hodgkin lymphoma, likely to be repre-
sentative of the population that is met in clinical practice, 
we aimed to assess extensively and systematically the 
inter-observer agreement for MTV measurement, com-
puted with three SUV thresholds, SUV >4, SUV >2.5, 
and SUV >41% of SUVmax, and to evaluate for each 
threshold the reproducibility among three open-source 
software platforms, BI for Fiji, Lifex, and Accurate. In 
addition, our aim was also to assess, despite the differ-
ences among software in pre-processing algorithms, if 
two or more software were able to give analogous MTV 




We retrospectively analyzed 121 patients of the 
Hematology Unit of our hospital, with a first histological 
diagnosis of Hodgkin lymphoma between 2010 and 2017, 
both in stage I–II and advanced. The clinical characteris-
tics of the patient population are summarized in Table 1.
All patients were treated according to EORTC/GHSH 
recommendations.
The staging 18F-FDG PET was the essential require-
ment for entering the study. Only patients whose MTV 
was calculable were included.
Image acquisition
PET scans, from the mid skull to pelvis (standard lym-
phoma), were obtained 60 ± 10 min after FDG injec-
tion in a Gemini TF system (Philips Medical System, 
Cleveland, Ohio, USA). In particular cases, for example, 
the presence of known distal involvement, the acquisition 
fields have been extended. A clinical acquisition protocol 
was used with injection of 0.1 mCi/kg of 18F-FDG after 
at least 4 h of fasting and documentation of blood glucose 
<200 mg/dl. Before PET scans, a low dose CT (120 kV; 
50–80 mA) was acquired to allow attenuation correction 
and lesions localization. PET images were reconstructed 
using an iterative algorithm (3D LOR RAMLA recon-
struction with TOF, FOV: 576, matrix: 144 × 144, voxel 
dimension: 4 × 4 × 4 mm).
Data analysis
PET images were independently evaluated by three 
readers (two nuclear medicine physicians and a resident 
in nuclear medicine), who measured MTV using three 
open-source software platforms, Beth-Israel (BI) plugin 
for Fiji [13], LifeX (Orlhac F, Nioche C, Buvat I. LIFEx 
user guide. LIFEx version 5.nn, Last update: June 12, 
2019, https://www.lifexsoft.org) and Accurate [14].
Each measurement was performed with three different 
SUV thresholding methods, two based on the absolute 
SUV value, SUV >2.5 and SUV >4, and one relative, SUV 
>41% of the SUV max of each lesion.
SUV max and SUV peak of the reference lesion were also 
evaluated, calculated in SUVbw units for both variables.
Using Accurate, SUVpeak was measured as the SUVmean 
in a 1-ml volume of interest (VOI), positioned such to 
provide the highest value across all positions within the 
tumor (SUVpeak at maximum peak). Using Fiji, SUVpeak 
was calculated as the average SUV included in a 1-cm3 
region of interest (ROI) centered on SUVmax (SUVpeak 
at maximum). LifeX does not assess SUVpeak.
In order to make segmentation more automatic and less 
user-dependent as possible, we kept default settings sug-
gested by the manufacturers in the user guides, in par-
ticular settings for each software were the following. In 
BI for Fiji, only SUV threshold (2.5; 4; 41%) and maxi-
mum SUV that can be processed (200) were set, without 
selecting the ‘use CT’ option. In LifeX, the initial thresh-
olds were set as follows: absolute SUV threshold (set to 
2.2) and Pruning Volume (set to 0.5 ml). In Accurate, the 
lower volume was set to 0.5 ml, as in LifeX. The software 
default settings have been maintained also for the maxi-
mum volume allowed (500 ml Fiji, 1000 ml LifeX, 500 ml 
Accurate).
Table 1  Patient characteristics
Age (mean ± SD) 40 ± 15.59
Gender (M:F) 1.05
Stage (%) I = 1.1
 II = 50.5
 III = 30.1
 IV = 18.3
Symptomsa (%) a = 64.5
 b = 35.5
aa, asymptomatic; b, B symptoms.
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In several cases, the operators had to manipulate the auto-
matically outlined ROI to obtain an MTV value suitable 
for a hypothetical clinical use. The regions containing only 
physiological FDG uptake (brain, bladder, kidney, intes-
tine, etc.) have been edited out. Furthermore, when the 
pathological tissue was automatically incorporated into 
the same ROI with adjacent physiologically active tissue, 
the ROI was removed and was redesigned by defining the 
limits of the VOI. This was done by defining the limits of 
the slices in which the lesion was included and redesign-
ing it semi-automatically in Fiji (‘draw’ function), by the 
ROI 3D function, subtype ‘click’ in Lifex, by the ‘mask’ 
function on the ‘Volume of interest’ page in Accurate. 
At SUV >41% of the SUV max threshold, Accurate did 
not identify many lesions, despite SUV above the initial 
threshold SUV >4, which were added manually, as sug-
gested by the user guide, on the ‘Volume of interest’ page 
or with the function ‘Mask’ or by clicking directly on the 
lesions in mode ROI 41% max, at the operator’s discretion.
Ease of use and differences among software platforms in 
the segmentation method were also considered.
Statistical analysis
Statistical analysis was performed with the SPSS soft-
ware (SPSS25). Quantitative variables, MTV, SUV max, 
and SUV peak, were expressed as means. Inter-observer 
agreement for MTV values was quantified as corre-
lation consistency through the Intraclass Correlation 
Coefficient (ICC). To bring out the differences among 
methods, post-hoc analyses were performed by testing 
the Pearson coefficient (r), evaluated separately for each 
software, and for each threshold. Reproducibility across 
software platforms was also quantified with the ICC and 
the Pearson coefficients were assessed. A single reader 
data was used to obtain ICCs among software platforms. 
Post-hoc analyses were performed for all readers. Finally, 
MTV and SUV max values were tested with the General 
Linear Model (GLM) for repeated measurements with 
Bonferroni correction to highlight and quantify the effect 
of the reader and of the software.
Results
Patients
MTV was computable in 121 patients with newly diag-
nosed Hodgkin lymphoma. Ten patients from the original 
database were excluded, of whom four had disseminated 
disease, two had diffuse brown fat activation, and one 
had coexistence of other FDG avid pathology, all inter-
fering with processing, two had inconsistent SUV due to 
incorrect normalization by the patient weight and one 
could not be processed by any of the three platforms, 
due to technical problems. In addition, LifeX with one 
or more thresholds (i.e., SUV >2.5 and SUV >41%) and 
Accurate SUV >41% of SUV max were not feasible in 
seven patients and in two patients, respectively, owing to 
technical problems.
Inter-observer reproducibility
Average MTV values obtained by the three readers using 
each thresholding method and ICCs are presented in 
Tables 2 and 3
All ICCs were excellent (ICC >0.9), except for Accurate 
SUV >41% of SUV max (ICC = 0.8).
The highest correlations were found for all software 
platforms at the SUV >4 thresholds, especially using 
LifeX and Accurate. The second best was the SUV >2.5 
threshold.
In the post-hoc inter-observer analysis, Fiji had the 
strongest Pearson correlation at the SUV >4 threshold (r = 
0.994). Fiji did not show the highest correlation between 
a pair of observers for a given threshold compared to the 
other software; however, the correlation coefficients were 
all excellent (r ≥ 0.9).
LifeX showed the maximum inter-observer agreement 
at the SUV >4 threshold (r = 1), followed by SUV >2.5 
threshold, which had a slightly weaker correlation. We 
obtained the minimum correlation at SUV > 41% of SUV 
max threshold (r ~ 0.8). Accurate behaved like LifeX, 
mostly with fixed thresholds: the maximum correlation 
is at SUV >4 (r = 1), the second-highest correlation was 
using SUV >2.5. At SUV >41% of SUV max threshold, the 
agreement among readers was the weakest (r ~ 0.6–0.7). 
In multivariate analysis for repeated measurements, we 
observed a statistically significant reader effect using 
Accurate at the SUV >41% of SUV max threshold (P < 
0.001) (Fig.  1). This effect was related to the fact that 
reader 2 gave MTV measurements significantly different 
from reader 1 and reader 3 (difference reader 2 – reader 1 
= −30.1 ml and difference reader 2 – reader 3 = −17.4 ml).
Table 2 Average MTV values by the readers
MTV Reader 1 Reader 2 Reader 3
MTV FIJI 41% 125.7 119.8 127.7
LIFEX 41% 117.2 110.6 112.1
ACCURATE 41% 175.1 102.0 142.0
MTV FIJI 4 100.2 95.0 100.0
LIFEX 4 106.5 106.3 106.3
ACCURATE 4 107.3 106.6 107.1
FIJI 2.5 174.1 166.5 176.1
LIFEX 2.5 222.1 225.5 227.2
ACCURATE 2.5 233.4 232.3 231.5
ICC, Intraclass Correlation Coefficient; MTV, metabolic tumor volume.
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Using the fixed thresholds, both SUV >4 and SUV >2.5, 
no statistically significant differences were found among 
reader measurements with any of the three software plat-
forms (P > 0.1) (Fig. 2).
MTV reproducibility across software platforms
The average MTV values using the three software plat-
forms and ICCs at each threshold are summarized in 
Tables 4 and 5.
The SUV >4 threshold showed the highest correlation 
among software at ICC analysis (ICC >0.99). At post-
hoc analysis, reader 1 obtained the maximum corre-
lations at the SUV >4 threshold (r > 0.99), using any 
software, above all between Fiji and Accurate. Reader 
2 showed the strongest correlation between LifeX and 
Accurate at the SUV >4 threshold (r =1), while the sec-
ond best was between LifeX and Accurate at the SUV 
>2.5 threshold. Reader 3 measurements showed the 
maximum correlations at the SUV >4 threshold, the 
Fig. 1
Average MTV values by the readers using Accurate SUV >41% of SUV max.
Fig. 2
Average MTV values by the readers at the SUV >4 threshold using each software platform.
Table 4 Average MTV values using the three software platforms 
(single reader data)
MTV FIJI LIFEX ACCURATE
41% 142.8 123.1 177.5
4 107.5 118.3 114.8
2.5 185.8 235.0 238.1
MTV, metabolic tumor volume.





ICC, Intraclass Correlation Coefficient.
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highest between LifeX and Accurate (r = 1), followed 
by Fiji and Accurate.
At SUV >41% of SUV max threshold, multivariate analy-
sis for repeated measurements showed a statistically sig-
nificant effect of the software on MTV value (P = 0.002), 
linked to a significant difference between LifeX and 
Accurate (difference Accurate – LifeX = 27.7 ml).
The multivariate tests showed a software effect on the 
SUV >4 threshold, due to a statistically significant dif-
ference (P = 0.035) between Fiji and LifeX (difference 
LifeX– Fiji = 8  ml). The variability between Fiji and 
Accurate was borderline. No statistically significant dif-
ference was found between LifeX and Accurate (Fig. 3).
We observed a marked software effect on MTV meas-
urement at SUV >2.5 threshold (P < 0.001), with signifi-
cantly higher values using LifeX and Accurate compared 
to Fiji (difference LifeX – Fiji = 61.14 ml and difference 
Accurate – Fiji = 60.16 ml) (Fig. 4).
SUV reproducibility
Inter-observer agreement for SUV max and SUV peak and 
the average values by the readers are given in Tables 6–9.
Both SUV max and SUV peak had ICCs all greater than 
0.99. The correlation among observers is greater with 
SUV peak than with SUV max at any threshold.
The GLM model applied to SUV max values showed 
a statistically significant effect related to the software 
used (P = 0.02) brought by LifeX, which gave an SUV 
max value significantly higher than Accurate (difference 
LifeX – Accurate = 0.05).
There were no statistically significant effects related to 
the reader (P > 0.4) or to the method used (P > 0.6).
Discussion
Despite the strong prognostic impact of MTV in lympho-
mas, a plethora of methods and software platforms are 
available for its calculation and no consensus has been 
reached on the best methodology. The preliminary eval-
uation of the reproducibility of the various thresholding 
methods is essential for the validation of the best method, 
but in the literature, an extensive and systematic analysis 
has not yet been conducted. We designed this study to 
evaluate the reproducibility of MTV measurements both 
in terms of interobserver agreement and stability among 
software platforms. We examined two published SUV 
thresholding methods, SUV >2.5 and SUV >41% of SUV 
max and a fixed threshold not yet applied in literature on 
lymphomas, SUV >4. Ease of use and differences among 
software platforms and thresholding methods in process-
ing have also been considered.
Regarding differences in the segmentation, VOIs pattern 
and VOIs number depended on the threshold applied 
as well as the software used. The SUV >4 segmentation 
produced a limited number of clean VOIs, well dichot-
omized between tumor and aspecific uptake, but the 
less active portions of the tumor were excluded from 
the segmented volume. VOIs produced by a lower SUV 
Fig. 3
Software comparison at the SUV >4 threshold. The bars represent average MTV values by the readers using the three software platforms and the 
solid line shows the MTV overall mean for the threshold.
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threshold of 2.5, instead, were wider and more represent-
ative disease volume but with the disadvantage of a more 
difficult separation of the tumor from adjacent aspecific 
uptake voxels, in particular, using LifeX. Indeed, large 
SUV >2.5 VOIs tended to be mixed between tumor/
physiological uptake in bulky disease with heteroge-
neous uptake. Thresholding based on low SUV cutoffs, 
SUV >2.5 and SUV >41% of SUVmax using LifeX (lower 
SUV allowable = 2.2), produced a number of aspecific 
VOIs corresponding to physiological sites of uptake. This 
required more complex editing out phase than the SUV 
>4 threshold.
Regarding reproducibility assessment, in this study, the 
inter-observer agreement for MTV values was excellent 
with all thresholds. Accurate SUV >41% of SUV max 
was an exception, showing a lower reproducibility. We 
obtained the best results with fixed thresholds accord-
ing to previous comparative studies [1,12]. We had the 
strongest inter-observer agreement at the SUV >4 thresh-
old, the second best was SUV >2.5. The slightly better 
Fig. 4
Software comparison at the SUV >2.5 threshold. The bars represent average MTV values by the readers using the three software platforms and 
the solid line shows the MTV overall mean for the threshold.
Table 6 Average SUV max by the readers
SUV MAX Reader 1 Reader 2 Reader 3
FIJI 41% 11.49 11.38 11.41
LIFEX 41% 11.27 11.19 11.26
ACCURATE 41% 11.27 11.15 11.26
FIJI 4 11.49 11.38 11.37
LIFEX 4 11.44 11.35 11.42
ACCURATE 4 11.35 11.26 11.34
FIJI 2.5 11.44 11.32 11.31
LIFEX 2.5 11.33 11.26 11.31
ACCURATE 2.5 11.22 11.15 11.20
Table 7 Average SUV peak by the readers
SUV PEAK Reader 1 Reader 2 Reader 3
FIJI 41% 9.01 8.98 8.95
ACCURATE 41% 8.81 8.73 8.79
FIJI 4 9.06 9.04 8.95
ACCURATE 4 8.87 8.83 8.86
FIJI 2.5 8.90 8.87 8.80
ACCURATE 2.5 8.80 8.74 8.79











ICC, Intraclass Correlation Coefficient.
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performance of the SUV >4 threshold, compared to SUV 
>2.5, is linked to its greater ease and automaticity: at SUV 
>4 threshold software were very specific. They found 
fewer physiological uptakes, leading to very little oper-
ator intervention. However, at SUV >4 threshold, MTV 
values resulted significantly lower compared with SUV 
>2.5 threshold. Indeed SUV >4 threshold considered 
only the areas of very intense hypermetabolism, equal to 
twice the liver uptake and underestimated the volume of 
the disease. An SUV >2.5 threshold, which should con-
sider all the areas of hypermetabolism above liver uptake, 
seemed to allow a more accurate anatomical definition of 
the disease volume.
The Fiji software, even if it did not gain the strongest 
agreement among readers, in general showed the best 
inter-observer reproducibility. Indeed, correlations 
among readers were excellent at any threshold. This is 
related to favorable program features: preselection of 
lesions, the effectiveness of the editing-out phase, good 
spatial resolution and ease of use, which minimize oper-
ator intervention. An important determinant of inter-ob-
server variability was the ROI manipulation by the 
operators, when lesions were automatically included in 
the same volume with adjacent physiological uptakes. 
For example: parapharyngeal lymph nodes/oropharynx, 
external iliac lymphadenopathy/bladder, or mediastinal 
bulky disease/bone, in presence of diffuse bone-mar-
row uptake. Manual intervention was rarely required 
using Fiji, while it had a strong impact on a purely 
thresholding segmentation software, such as LifeX and 
Accurate.
The SUV >41% of the SUV max threshold was signifi-
cantly influenced by the reader using Accurate and shows 
great variability among software platforms. While the 
fixed thresholds are based on a simple volume calcula-
tion on the absolute value of SUV, the relative threshold 
algorithm is based on a percentage of uptake, resulting in 
more complex and exposed to ROI drawing variability. 
We noted a processing pitfall using Accurate SUV >41% 
of SUV max in bulky disease with heterogeneous uptake. 
In such cases, it was necessary sometimes to modify the 
volume semi-automatically or even manually, possibly 
increasing measurement variability. Therefore, the use 
of the SUV >41% of SUV max threshold should not be 
recommended with Accurate. As previously suggested 
by Barrington and colleagues in a study on patients with 
DLBCL [1], and also according to the analysis of our data 
on patients with Hodgkin lymphoma, the SUV >41% of 
SUV max threshold appears less performant in lesions 
with marked uptake heterogeneity, such as bulky lesions, 
since the automatic processing with the relative thresh-
old failed in several cases, making it necessary a semi-au-
tomatic or manual intervention. Such a relative threshold 
appears to be more suitable for the study of solid tumors, 
than for lymphomas.
The fixed thresholds, both SUV >4 and SUV >2.5 were 
not influenced by the reader, but only by the software 
used. MTV values were significantly underestimated by 
Fiji compared to LifeX and Accurate. This could be due 
to Fiji’s lower sensitivity since it is less performant in 
detecting small and not intense lesions. The reproduc-
ibility between LifeX and Accurate is excellent so that 
they can be considered interchangeable. Therefore, we 
could suggest that if using more than one software in a 
study is needed, in particular in multicentric studies, the 
use of LifeX and Accurate with fixed thresholds should 
be considered.
Finally, we found an optimal reproducibility of SUV val-
ues both among readers and among software platforms, 
with a better reproducibility of SUV peak compared to 
SUV max. The fact that all PET scans were performed 
on the same PET system and with the same acquisi-
tion protocol, certainly contributed to this finding. The 
greater reproducibility of SUV peak compared to SUV 
max is in line with data from the literature [15,16]. SUV 
peak, an average SUV calculated in a fixed-size VOI 
containing more pixels, was defined to be more reliable 
for the quantification of uptake than SUV max, which 
represents a single pixel and may reflect mere statistical 
fluctuations of activity in relation to the duration of the 
acquisition.
In conclusion, our study shows that all three thresholds 
studied are suitable for MTV computation in terms 
of reproducibility. Our major result is that an excellent 
inter-observer agreement and the best stability among 
software platforms is obtained with fixed thresholds, both 
SUV >4 and SUV >2.5, regardless of the software used. 
If more than one software has to be used in a study, we 
suggest the use of fixed thresholds, and the two programs 
LifeX and Accurate.
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